Pharmaco-redox regulation of cytokine-related pathways: From receptor signaling to pharmacogenomics

Free Radical Biology and Medicine

Volumn 33, Issue 7, 2002, Pages 907-926

  Haddad, John J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cytokine; Free radicals; Glutathione; Immunopharmacology; Neuroimmunology; Oxidants; Redox; Reductants; ROS; Transcription factors

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; MITOGEN ACTIVATED PROTEIN KINASE; RECEPTOR PROTEIN; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA;

CELL FUNCTION; CELL INTERACTION; DRUG ACTIVITY; ENZYME ACTIVITY; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOLOGY; PHARMACOGENOMICS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW;

ANIMALS; CYTOKINES; GENOMICS; HUMANS; OXIDATION-REDUCTION; PHARMACOLOGY; SIGNAL TRANSDUCTION;

EID: 0036802207     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(02)00985-1     Document Type: Review

References (305)

1. Nicod L.P. Cytokines overview. Thorax. 48:1993;660-667.
2. Rouveix B. Clinical pharmacology of cytokines. Eur. Cytokine Netw. 8:1997;291-293.
3. Boraschi D., Cifone M.G., Falk W., Flad H.-D., Tagliabue A., Martin M.U. Cytokines in inflammation. Eur. Cytokine Netw. 9:1998;205-212.
4. Dinarello C.A. Pro-inflammatory cytokines. Chest. 118:2000;503-508.
5. Oppenheim J.J. Cytokines past, present, and future. Int. J. Hematol. 74:2001;3-8.
6. Holloway A.F., Rao S., Shannon M.F. Regulation of cytokine gene transcription in the immune system. Mol. Immunol. 38:2002;567-580.
7. Tyson J.J., Chen K., Novak B. Network dynamics and cell physiology. Nat. Rev. Mol. Cell Biol. 2:2001;908-916.
8. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:1996;397-440.
9. Maslinska D. The cytokine network and interleukin-15 (IL-15) in brain development. Folia Neuropathol. 39:2001;43-47.
10. Deeg H.J. Cytokines in graft-versus-host disease and the graft-versus-leukemia reaction. Int. J. Hematol. 74:2001;26-32.
11. Segel L.A. Controlling the immune system diffuse feedback via a diffuse informational network. Novartis Found. Symp. 239:2001;31-40.
12. Akdis M., Trautmann A., Klunker S., Blaser K., Akdis C.A. Cytokine network and dysregulated apoptosis in atopic dermatitis. Acta Odontol. Scand. 59:2001;178-182.
13. Parkin J., Cohen B. An overview of the immune system. Lancet. 357:2001;1777-1789.
14. Chang H., Lau A.L., Matzuk M.M. Studying TGF-β superfamily signaling by knockouts and knockins. Mol. Cell. Endocrinol. 180:2001;39-46.
15. Joyce S. Immune recognition, response, and regulation how T lymphocytes do it. Immunol. Res. 23:2001;215-228.
16. Kile B.T., Nicola N.A., Alexander W.S. Negative regulators of cytokine signaling. Int. J. Hematol. 73:2001;292-298.
17. Pastor C.M., Frossard J.L. Are genetically modified mice useful for the understanding of acute pancreatitis? FASEB J. 15:2001;893-897.
18. Yan C., Matzuk M.M. Transgenic models of ovarian failure. J. Soc. Gynecol. Investig. 8:2001;S30-S33.
19. Sato M., Taniguchi T., Tanaka N. The interferon system and interferon regulatory factor transcription factors studies from gene knockout mice. Cytokine Growth Factor Rev. 12:2001;133-142.
20. Hiscott J. Introduction - cytokine receptors, signaling pathways and viruses. Cytokine Growth Factor Rev. 12:2001;129-131.
21. Shakhov A.N., Nedospasov S.A. Expression profiling in knockout mice lymphotoxin versus tumor necrosis factor in the maintenance of splenic micro-architecture. Cytokine Growth Factor Rev. 12:2001;107-119.
22. Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 2:2002;135-149.
23. van der Poll T., de Jonge E., Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin. Thromb. Hemost. 27:2001;639-651.
24. Bown M.J., Nicholson M.L., Bell P.R., Sayers R.D. Cytokines and inflammatory pathways in the pathogenesis of multiple organ failure following abdominal aortic aneurysm repair. Eur. J. Vasc. Endovasc. Surg. 22:2001;485-495.
25. Fahy J.V. Remodeling of the airway epithelium in asthma. Am. J. Respir. Crit. Care Med. 164:2001;S46-S51.
26. Tilg H. Cytokines and liver diseases. Can. J. Gastroenterol. 15:2001;661-668.
27. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 92:2001;1684-1688.
28. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12:2001;53-72.
29. Smith P.C., Hobisch A., Lin D.L., Culig Z., Keller E.T. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. 12:2001;33-40.
30. Bauer J., Rauschka H., Lassmann H. Inflammation in the nervous system the human perspective. Glia. 36:2001;235-243.
31. Henderson B., Poole S., Wilson M. Bacterial modulins a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Microbiol. Rev. 60:1996;316-341.
32. Ulevitch R.J., Tobias P.S. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:1995;437-457.
33. Hersh D., Weiss J., Zychlinsky A. How bacteria initiate inflammation aspects of the emerging story. Curr. Opin. Microbiol. 1:1998;43-48.
34. Turcanu V., Williams N.A. Cell identification and isolation on the basis of cytokine secretion a novel tool for investigating immune responses. Nat. Med. 7:2001;373-376.
35. Freudenberg M.A., Merlin T., Gumenscheimer M., Kalis C., Landmann R., Galanos C. Role of lipopolysaccharide susceptibility in the innate immune response to Salmonella typhimurium infection LPS, a primary target for recognition of Gram-negative bacteria. Microbes Infect. 3:2001;1213-1222.
36. Alexander C., Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7:2001;167-202.
37. Hawiger J. Innate immunity and inflammation a transcriptional paradigm. Immunol. Res. 23:2001;99-109.
38. Thorn J. The inflammatory response in humans after inhalation of bacterial endotoxin a review. Inflamm. Res. 50:2001;254-261.
39. Stevens D.L. Superantigens their role in infectious diseases. Immunol. Invest. 26:1997;275-281.
40. Schiffenbauer J. Superantigens and their role in autoimmune disorders. Arch. Immunol. Ther. Exp. (Warsz.). 47:1999;17-24.
41. Papiernik M. Natural CD4+ CD25+ regulatory T cells their role in the control of superantigen responses. Immunol. Rev. 182:2001;180-189.
42. Posnett D.N., Yarilina A.A. Sleeping with the enemy - endogenous superantigens in humans. Immunity. 15:2001;503-506.
43. Muller-Alouf H., Carnoy C., Simonet M., Alouf J.E. Superantigen bacterial toxins state of the art. Toxicon. 39:2001;1691-1701.
44. Miyajima A., Kitamura T., Harada N., Yokota T., Arai K. Cytokine receptors and signal transduction. Annu. Rev. Immunol. 10:1992;295-331.
45. Taniguchi T. Regulation of cytokine gene expression. Annu. Rev. Immunol. 6:1988;439-464.
46. Raber J., Sorg O., Horn T.F., Yu N., Koob G.F., Campbell I.L., Bloom F.E. Inflammatory cytokines putative regulators of neuronal and neuro-endocrine function. Brain Res. Brain Res. Rev. 26:1998;320-326.
47. Nesin M., Cunningham-Rundles S. Cytokines and neonates. Am. J. Perinatol. 17:2000;393-404.
48. Weaver J.C., McGrath P., Adams S. Gel microdrop technology for rapid isolation of rare and high producer cells. Nat. Med. 3:1997;583-585.
49. Gray F., Kenney J.S., Dunne J.F. Secretion capture and report web use of affinity derivatized agarose microdroplets for the selection of hybridoma cells. J. Immunol. Methods. 182:1995;155-163.
50. Scheffold A., Assenmacher M., Reiners-Schramm L., Lauster R., Radbruch A. High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines γ-interferon and interleukin-10 on the surface of cytokine-secreting cells. Nat. Med. 6:2000;107-110.
51. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA. 87:1990;6934-6938.
52. Bischoff S.C., de Weck A.L., Dahinden C.A. Peptide analogs of consensus receptor sequence inhibit the action of cytokines on human basophils. Lymphokine Cytokine Res. 11:1992;33-37.
53. Cosman D., Lyman S.D., Idzerda R.L., Beckmann M.P., Park L.S., Goodwin R.G., March C.J. A new cytokine receptor superfamily. Trends Biochem. Sci. 15:1990;265-270.
54. Fernandez-Botran R. Soluble cytokine receptors their role in immunoregulation. FASEB J. 5:1991;2567-2574.
55. Kishimoto T., Taga T., Akira S. Cytokine signal transduction. Cell. 76:1994;253-262.
56. Lutfalla G., Gardiner K., Uze G. A new member of the cytokine receptor gene family maps on chromosome 21 at less than 35 kb from IFNαR. Genomics. 16:1993;366-373.
57. Beschin A., Bilej M., Torreele E., De Baetselier P. On the existence of cytokines in invertebrates. Cell. Mol. Life Sci. 58:2001;801-814.
58. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7:2001;1127-1135.
59. Bleesing J.J., Fleisher T.A. Cell function-based flow cytometry. Semin. Hematol. 38:2001;169-178.
60. Schein C.H. Producing soluble recombinant RNases and assays to measure their interaction with interferon-gamma in vitro. Methods Mol. Biol. 160:2001;113-137.
61. House R.V. Cytokine measurement techniques for assessing hypersensitivity. Toxicology. 158:2001;51-58.
62. Mulder K.M. Role of Ras and MAPKs in TGF-β signaling. Cytokine Growth Factor Rev. 11:2000;23-35.
63. Pennica D., Wood W.I., Chien K.R. Cardiotrophin-1 a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 7:1996;81-91.
64. Ekerfelt C., Ernerudh J., Jenmalm M.C. Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro comparison of ELISPOT, a novel ELISA and real-time RT-PCR. J. Immunol. Methods. 260:2002;55-67.
65. Neff L., Zeisel M., Sibilia J., Scholler-Guinard M., Klein J.P., Wachsmann D. NF-κB and the MAP kinases/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. Cell. Microbiol. 3:2001;703-712.
66. Bieche I., Franc B., Vidaud D., Vidaud M., Lidereau R. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 11:2001;147-152.
67. Miyajima A., Kitamura T., Harada N., Yokota T., Arai K. Cytokine receptors and signal transduction. Annu. Rev. Immunol. 10:1992;295-331.
68. Miyajima A., Hara T., Kitamura T. Common subunits of cytokine receptors and the functional redundancy of cytokines. Trends Biochem. Sci. 17:1992;378-382.
69. Miyazaki T., Maruyama M., Yamada G., Hatakeyama M., Taniguchi T. The integrity of the conserved 'WS motif' common to IL-2 and other cytokine receptors is essential for ligand binding and signal transduction. EMBO J. 10:1991;3191-3197.
70. Murakami M., Narazaki M., Hibi M., Yawata H., Yasukawa K., Hamaguchi M., Taga T., Kishimoto T. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc. Natl. Acad. Sci. USA. 88:1991;11349-11353.
71. Olsson I., Gullberg U., Lantz M., Richter J. The receptors for regulatory molecules in hematopoiesis. Eur. J. Haematol. 48:1992;1-9.
72. Schreurs J., Gorman D.M., Miyajima A. Cytokine receptors a new superfamily of receptors. Int. Rev. Cytol. 137B:1992;121-155.
73. Sprang S.R., Bazan J.F. Cytokine structural taxonomy and mechanisms of receptor engagement. Curr. Biol. 3:1993;815-827.
74. Yoshimura A., Zimmers T., Neumann D., Longmore G., Yoshimura Y., Lodish H.F. Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor. J. Biol. Chem. 267:1992;11619-11625.
75. de Lemos M.L. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann. Pharmacother. 35:2001;1118-1121.
76. Ashby J. Getting the problem of endocrine disruption into focus the need for a pause for thought. APMIS. 108:2000;805-813.
77. Barnes S., Boersma B., Patel R., Kirk M., Darley-Usmar V.M., Kim H., Xu J. Isoflavonoids and chronic disease mechanisms of action. Biofactors. 12:2000;209-215.
78. Polkowski K., Mazurek A.P. Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol. Pharm. 57:2000;135-155.
79. Hollenberg M.D. Tyrosine kinase-mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle. Mol. Cell. Biochem. 149-150:1995;77-85.
80. Monteseirin J., Prados M., Guardia P., Delgado J., de la Calle A., Camacho M.J., Conde M.A., Conde J. Formation of lipids, peptides and cytokines. Allergol. Immunopathol. (Madr.). 24:1996;211-218.
81. Yavin E., Glozman S., Green P. Docosahexaenoic acid accumulation in the prenatal brain prooxidant and antioxidant features. J. Mol. Neurosci. 16:2001;229-235.
82. Kagan V.E., Kozlov A.V., Tyurina Y.Y., Shvedova A.A., Yalowich J.C. Antioxidant mechanisms of nitric oxide against iron-catalyzed oxidative stress in cells. Antioxid. Redox Signal. 3:2001;189-202.
83. Haddad J.J., Olver R.E., Land S.C. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J. Biol. Chem. 275:2000;21130-21139.
84. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J. Biol. Chem. 269:1994;9397-9400.
85. Hayes J.D., McLellan L.I. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defense against oxidative stress. Free Radic. Res. 31:1999;273-300.
86. Therond P., Bonnefont-Rousselot D., Davit-Spraul A., Conti M., Legrand A. Biomarkers of oxidative stress an analytical approach. Curr. Opin. Clin. Nutr. Metab. Care. 3:2000;373-384.
87. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21:2001;2-14.
88. Rimbach G., Hohler D., Fischer A., Roy S., Virgili F., Pallauf J., Packer L. Methods to assess free radicals and oxidative stress in biological systems. Arch. Tierernahr. 52:1999;203-222.
89. Sies H. Strategies of antioxidant defense. Eur. J. Biochem. 215:1993;213-219.
90. Bankson D.D., Kestin M., Rifai N. Role of free radicals in cancer and atherosclerosis. Clin. Lab. Med. 13:1993;463-480.
91. Nathan L., Chaudhuri G. Antioxidant and prooxidant actions of estrogens potential physiological and clinical implications. Semin. Reprod. Endocrinol. 16:1998;309-314.
92. Reiter R.J., Guerrero J.M., Garcia J.J., Acuna-Castroviejo D. Reactive oxygen intermediates, molecular damage, and aging. Relation to melatonin. Ann. NY Acad. Sci. 854:1998;410-424.
93. Lynch T., Cherny R.A., Bush A.I. Oxidative processes in Alzheimer's disease the role of a β-metal interactions. Exp. Gerontol. 35:2000;445-451.
94. Haselton P.S., Roberts T.E. Adult respiratory distress syndrome an update. Histopathology. 34:1999;285-294.
95. Saugstad O.D. Oxygen radicals and pulmonary damage. Pediatr. Pulmonol. 1:1985;167-175.
96. Haddad J.J. Glutathione depletion is associated with augmenting a pro-inflammatory signal evidence for an antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell. Mol. Ther. 6:2000;177-187.
97. Saugstad O.D. Bronchopulmonary dysplasia and oxidative stress are we closer to an understanding of the pathogenesis of BPD? Acta Paediatr. 86:1997;1277-1282.
98. Cantin A.M., Hubbard R.C., Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. 139:1989;370-372.
99. Bunnell E., Pacht E.R. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 148:1993;1174-1178.
100. Roum J.H., Behld R., McElvancy N.G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 75:1993;2419-2424.
101. Rahman I. Inflammation and the regulation of glutathione level in lung epithelial cells. Antioxid. Redox Signal. 1:1999;425-447.
102. Rahman I., MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. 16:2000;534-554.
103. Rahman I., MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation therapeutic approaches. Free Radic. Biol. Med. 28:2000;1405-1420.
104. Semenza G.L. Oxygen-regulated transcription factors and their role in pulmonary disease. Respir. Res. 1:2000;159-162.
105. Bruick R.K., McKnight S.L. Transcription enhanced oxygen sensing gets a second wind. Science. 295:2002;807-808.
106. van der Vliet A., Cross C.E. Oxidants, nitrosants, and the lung. Am. J. Med. 109:2000;398-421.
107. McCord J.M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244:1969;6049-6055.
108. McCord J.M., Fridovich I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J. Biol. Chem. 244:1969;6056-6063.
109. Babior B.M., Kipnes R.S., Curnutte J.T. Biological defense mechanisms the production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52:1973;741-744.
110. Granger D.N., Rutili G., McCord J.M. Superoxide radicals in feline intestinal ischemia. Gastroenterology. 81:1981;22-29.
111. Crichton R.R., Pierre J.L. Old iron, young copper from Mars to Venus. Biometals. 14:2001;99-112.
112. Macmillan-Crow L.A., Cruthirds D.L. Invited review manganese superoxide dismutase in disease. Free Radic. Res. 34:2001;325-336.
113. Lieu P.T., Heiskala M., Peterson P.A., Yang Y. The roles of iron in health and disease. Mol. Aspects Med. 22:2001;1-87.
114. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 279:2000;L1005-L1028.
115. Kazzaz J.A., Xu J., Palaia T.A., Mantell L., Fein A.M., Horowitz S. Cellular oxygen toxicity. J. Biol. Chem. 271:1996;15182-15186.
116. Vallance P. Nitric oxide. Biologist (London). 48:2001;153-158.
117. Wink D.A., Miranda K.M., Espey M.G., Pluta R.M., Hewett S.J., Colton C., Vitek M., Feelisch M., Grisham M.B. Mechanisms of the antioxidant effects of nitric oxide. Antioxid. Redox Signal. 3:2001;203-213.
118. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol. 11:2001;66-75.
119. Pullar J.M., Vissers M.C., Winterbourn C.C. Living with a killer the effects of hypochlorous acid on mammalian cells. IUBMB Life. 50:2000;259-266.
120. Winterbourn C.C., Kettle A.J. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic. Biol. Med. 29:2000;403-409.
121. Alder V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 18:1999;6104-6111.
122. Keane M.P., Strieter R.M. The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir. Res. 3:2002;5-11.
123. DeForge L.E., Fantone J.C., Kenney J.S., Remick D.G. Oxygen radical scavengers selectively inhibit interleukin-8 production in human whole blood. J. Clin. Invest. 90:1991;2123-2129.
124. Desmarquest P., Chadelat K., Corroyer S. Effect of hyperoxia on human macrophage cytokine response. Respir. Med. 92:1998;951-960.
125. Wang Z., Malmberg P., Ek A. Swine dust induces cytokine secretion from human epithelial cells and alveolar macrophages. Clin. Exp. Immunol. 115:1999;6-12.
126. Yoshida Y., Maruyama M., Fujita T., Arai N., Hayashi R., Araya J., Matsui S., Yamashita N., Sugiyama E., Kobayashi M. Reactive oxygen intermediates stimulate interleukin-6 production in human bronchial epithelial cells. Am. J. Physiol. 276:1999;L900-L908.
127. Meier B., Radeke H.H., Selle S. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumor necrosis factor-α Biochem. J. 263:1989;539-545.
128. Luster M.I., Simeonova P.P. Asbestos induces inflammatory cytokines in the lung through redox sensitive transcription factors. Toxicol. Lett. 102-103:1998;271-275.
129. 2/ROS) dependent release of IL-1β, IL-6 and TNF-α evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium. Cytokine. 13:2001;138-147.
130. Liu T.Z., Lee K.T., Chern C.L., Cheng J.T., Stern A., Tsai L.Y. Free radical-triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor-κB. Ann. Clin. Lab. Sci. 31:2001;383-390.
131. Sanlioglu S., Williams C.M., Samavati L., Butler N.S., Wang G., McCray P.B. Jr, Ritchie T.C., Hunninghake G.W., Zandi E., Engelhardt J.F. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-α secretion through IKK regulation of NF-κB. J. Biol. Chem. 276:2001;30188-30198.
132. Haddad J.J., Land S.C. Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-α biosynthesis. Br. J. Pharmacol. 135:2002;520-536.
133. Chandel N.S., Trzyna W.C., McClintock D.S., Schumacker P.T. Role of oxidants in NF-κB activation and TNF-α gene transcription induced by hypoxia and endotoxin. J. Immunol. 165:2000;1013-1021.
134. Simeonova P.P., Luster M.I. Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-α response from alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 12:1995;676-683.
135. 3 particles in human lung cells (A549). Toxicology. 166:2001;129-137.
136. 3 particles. Toxicol. Lett. 121:2001;107-117.
137. 3 particles-induced lung tissue injury role of free radicals. Cancer Lett. 167:2001;7-15.
138. 3 particles assessment of cellular membrane damage and antioxidant system disruption in human epithelial lung cells (L132) in culture. Toxicol. Lett. 117:2000;25-35.
139. Yeh M., Leitinger N., de Martin R., Onai N., Matsushima K., Vora D.K., Berliner J.A., Reddy S.T. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-α and oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21:2001;1585-1591.
140. Chen C.Y., Huang Y.L., Lin T.H. Association between oxidative stress and cytokine production in nickel-treated rats. Arch. Biochem. Biophys. 356:1998;127-132.
141. Fu K., Sarras M.P. Jr, De Lisle R.C., Andrews G.K. Expression of oxidative stress-responsive genes and cytokine genes during caerulein-induced acute pancreatitis. Am. J. Physiol. 273:1997;G696-G705.
142. Rovin B.H., Dickerson J.A., Tan L.C., Fassler J. Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status. Cytokine. 9:1997;178-186.
143. Sheikhi M., Gustafsson A., Jarstrand C. Cytokine, elastase and oxygen radical release by Fusobacterium nucleatum-activated leukocytes a possible pathogenic factor in periodontitis. J. Clin. Periodontol. 27:2000;758-762.
144. Ali M.H., Schlidt S.A., Chandel N.S., Hynes K.L., Schumacker P.T., Gewertz B.L. Endothelial permeability and IL-6 production during hypoxia role of ROS in signal transduction. Am. J. Physiol. 277:1999;L1057-L1065.
145. Floyd R.A. Neuro-inflammatory processes are important in neurodegenerative diseases an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. 26:1999;1346-1355.
146. Gougerot-Podicalo M.A., Elbim C., Chollet-Martin S. Modulation of the oxidative burst of human neutrophils by pro- and anti-inflammatory cytokines. Pathol. Biol. (Paris). 44:1996;36-41.
147. Sikora J.P. The role of cytokines and reactive oxygen species in the pathogenesis of sepsis. Pol. Merkuriusz. Lek. 7:2000;47-50.
148. Dokka S., Shi X., Leonard S., Wang L., Castranova V., Rojanasakul Y. Interleukin-10-mediated inhibition of free radical generation in macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:2001;L1196-L1202.
149. Darlington L.G., Stone T.W. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br. J. Nutr. 85:2001;251-269.
150. Reiter R.J., Calvo J.R., Karbownik M., Qi W., Tan D.X. Melatonin and its relation to the immune system and inflammation. Ann. NY Acad. Sci. 917:2000;376-386.
151. Sen C.K., Roy S. Antioxidant regulation of cell adhesion. Med. Sci. Sports Exerc. 33:2001;377-381.
152. Sieminska A. Perspectives for treatment of pulmonary fibrosis. Pneumonol. Alergol. Pol. 67:1999;576-582.
153. Exner R., Wessner B., Manhart N., Roth E. Therapeutic potential of glutathione. Wien. Klin. Wochenschr. 112:2000;610-616.
154. Han S.N., Meydani S.N. Antioxidants, cytokines, and influenza infection in aged mice and elderly humans. J. Infect. Dis. 182:2000;S74-S80.
155. Miyachi Y. Pharmacologic modulation of neutrophil functions. Clin. Dermatol. 18:2000;369-373.
156. MacNee W. Oxidants/antioxidants and COPD. Chest. 117:2000;303S-317S.
157. Knight J.A. Review free radicals, antioxidants, and the immune system. Ann. Clin. Lab. Sci. 30:2000;145-158.
158. Tomita M., Irwin K.I., Xie Z.J., Santoro T.J. Tea pigments inhibit the production of type 1 (Th1) and type 2 (Th2) helper T cell cytokines in CD4+ T cells. Phytother. Res. 16:2002;36-42.
159. Seo J.Y., Kim H., Seo J.T., Kim K.H. Oxidative stress induced cytokine production in isolated rat pancreatic acinar cells effects of small-molecule antioxidants. Pharmacology. 64:2002;63-70.
160. Blanchard J.A. 2nd, Barve S., Joshi-Barve S., Talwalker R., Gates L.K. Jr. Antioxidants inhibit cytokine production and suppress NF-κB activation in CAPAN-1 and CAPAN-2 cell lines. Dig. Dis. Sci. 46:2001;2768-2772.
161. Obermuller-Jevic U.C., Schlegel B., Flaccus A., Biesalski H.K. The effect of β-carotene on the expression of interleukin-6 and heme oxygenase-1 in UV-irradiated human skin fibroblasts in vitro. FEBS Lett. 509:2001;186-190.
162. Jain S.K., Kannan K. Chromium chloride inhibits oxidative stress and TNF-α secretion caused by exposure to high glucose in cultured U937 monocytes. Biochem. Biophys. Res. Commun. 289:2001;687-691.
163. De la Fuente M., Victor V.M. Ascorbic acid and N-acetylcysteine improve in vitro the function of lymphocytes from mice with endotoxin-induced oxidative stress. Free Radic. Res. 35:2001;73-84.
164. Shafer L.L., McNulty J.A., Young M.R. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J. Neuroimmunol. 120:2001;84-93.
165. Zhang J., Jiang S., Watson R.R. Antioxidant supplementation prevents oxidation and inflammatory responses induced by side-stream cigarette smoke in old mice. Environ. Health Perspect. 109:2001;1007-1009.
166. 2+ in the alveolar epithelium amelioration of endotoxin-induced cytokine release and partial amplification of a cytoprotective IL-10-sensitive pathway. Biochem. Biophys. Res. Commun. 274:2000;500-505.
167. Petroff M.G., Petroff B.K., Pate J.L. Mechanisms of cytokine-induced death of cultured bovine luteal cells. Reproduction. 121:2001;753-760.
168. Napoli C., Lerman L.O. Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. Mayo Clin. Proc. 76:2001;619-631.
169. Hudson V.M. Rethinking cystic fibrosis pathology the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30:2001;1440-1461.
170. Nathens A.B., Bitar R., Marshall J.C., Watson R.W., Dackiw A.P., Fan J., Hiscott J., Rotstein O.D. Antioxidants increase lipopolysaccharide-stimulated TNF-α release in murine macrophages role for altered TNF-α mRNA stability. Shock. 16:2001;361-367.
171. Parmentier M., Hirani N., Rahman I., Donaldson K., MacNee W., Antonicelli F. Regulation of lipopolysaccharide-mediated interleukin-1β release by N-acetylcysteine in THP-1 cells. Eur. Respir. J. 16:2000;933-939.
172. Haddad J.J., Safieh-Garabedian B., Saadé N.E., Land S.C. Thiol regulation of pro-inflammatory cytokines reveals a novel immunopharmacological potential of glutathione in the alveolar epithelium. J. Pharmacol. Exp. Ther. 296:2001;996-1005.
173. Haddad J.J., Land S.C. Amiloride blockades lipopolysaccharide-induced cytokine biosynthesis in an IκB-α/NF-κB-dependent mechanism evidence for the amplification of an anti-inflammatory pathway in the alveolar epithelium. Am. J. Respir. Cell Mol. Biol. 26:2002;114-126.
174. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., KowaLczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated pro-inflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300:2002;559-566.
175. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30:2001;1191-1212.
176. Sies H. Glutathione and its role on cellular functions. Free Radic. Biol. Med. 27:1999;916-921.
177. Breuille D., Obled C. Cysteine and glutathione in catabolic states. Nestle Nutr. Workshop Ser. Clin. Perform. Programme. 3:2000;173-191.
178. 2-evoked regulation of HIF-1α and NF-κB in perinatal lung epithelium requires glutathione biosynthesis. Am. J. Physiol. Lung Cell. Mol. Physiol. 278:2000;L492-L503.
179. Meister A. Glutathione metabolism and its selective modification. J. Biol. Chem. 263:1988;17205-17208.
180. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254:1979;7558-7560.
181. Griffith O.W., Anderson M.E., Meister A. Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n-propyl homocysteine sulfoximine), a selective inhibitor of γ-glutamylcysteine synthetase. J. Biol. Chem. 254:1979;1205-1210.
182. Griffith O.W., Meister A. Glutathione interorgan translocation, turnover, and metabolism. Proc. Natl. Acad. Sci. USA. 76:1979;5606-5610.
183. Soltaninassab S.R., Sekhar K.R., Meredith M.J., Freeman M.L. Multi-faceted regulation of γ-glutamylcysteine synthetase. J. Cell. Physiol. 182:2000;163-170.
184. Meister A. Glutathione metabolism. Methods Enzymol. 251:1995;3-7.
185. Meister A. Glutathione biosynthesis and its inhibition. J. Biol. Chem. 252:1995;26-30.
186. Rennie M.J., Bowtell J.L., Bruce M., Khogali S.E. Interaction between glutamine availability and metabolism of glycogen, tricarboxylic acid cycle intermediates and glutathione. J. Nutr. 131:2001;2488S-2490S.
187. Aschner M. Neuron-astrocyte interactions implications for cellular energetics and antioxidant levels. Neurotoxicology. 21:2000;1101-1107.
188. Lockwood T.D. Redox control of protein degradation. Antioxid. Redox Signal. 2:2000;851-878.
189. Rahman I. Regulation of nuclear factor-κB, activator protein-1 and glutathione levels by tumor necrosis factor-α and dexamethasone in alveolar epithelial cells. Biochem. Pharmacol. 60:2000;1041-1049.
190. Rahman I., Mulier B., Gilmour P.S., Watchorn T., Donaldson K., Jeffery P.K., MacNee W. Oxidant-mediated lung epithelial cell tolerance the role of intracellular glutathione and nuclear factor-κB. Biochem. Pharmacol. 62:2001;787-794.
191. Coe J.P., Rahman I., Sphyris N., Clarke A.R., Harrison D.J. Glutathione and p53 independently mediate responses against oxidative stress in ES cells. Free Radic. Biol. Med. 32:2002;187-196.
192. Arrigo A.P. Gene expression and the thiol redox state. Free Radic. Biol. Med. 27:1999;936-944.
193. Sen C.K., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
194. Sen C.K. Cellular thiols and redox-regulated signal transduction. Curr. Top. Cell. Regul. 36:2000;1-30.
195. Haddad J.J., Land S.C. The differential expression of apoptosis factors in the alveolar epithelium is redox sensitive and requires NF-κB (RelA)-selective targeting. Biochem. Biophys. Res. Commun. 271:2000;257-267.
196. Haddad J.J., Choudhary K.K., Land S.C. The ex vivo differential expression of apoptosis signaling cofactors in the developing lung essential role of oxygenation during the transition from placental to pulmonary-based
197. Deplancke B., Gaskins H.R. Redox control of the trans-sulfuration and glutathione biosynthesis pathways. Curr. Opin. Clin. Nutr. Metab. Care. 5:2002;85-92.
198. Forman H.J., Torres M. Redox signaling in macrophages. Mol. Aspects Med. 22:2001;189-216.
199. Fuchs J., Zollner T.M., Kaufmann R., Podda M. Redox-modulated pathways in inflammatory skin diseases. Free Radic. Biol. Med. 30:2001;337-353.
200. Cuozzo J.W., Kaiser C.A. Competition between glutathione and protein thiols for disulphide-bond formation. Nat. Cell Biol. 1:1999;130-135.
201. Berk B.C. Redox signals that regulate the vascular response to injury. Thromb. Haemost. 82:1999;810-817.
202. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Annu. Rev. Immunol. 15:1997;351-369.
203. Biesalski H.K., Frank J. Antioxidants in nutrition and their importance in the anti-oxidative balance in the immune system. Immun. Infekt. 23:1995;166-173.
204. Lavrovsky Y., Chatterjee B., Clark R.A., Roy A.K. Role of redox-regulated transcription factors in inflammation, aging and age-related diseases. Exp. Gerontol. 35:2000;521-532.
205. Thomas S.R., Stocker R. Antioxidant activities and redox regulation of interferon-γ-induced tryptophan metabolism in human monocytes and macrophages. Adv. Exp. Med. Biol. 467:1999;541-552.
206. Goossens V., De Vos K., Vercammen D., Steemans M., Vancompernolle K., Fiers W., Vandenabeele P., Grooten J. Redox regulation of TNF signaling. Biofactors. 10:1999;145-156.
207. Herrlich P., Bohmer F.D. Redox regulation of signal transduction in mammalian cells. Biochem. Pharmacol. 59:2000;35-41.
208. Finkel T. Redox-dependent signal transduction. FEBS Lett. 476:2000;52-54.
209. Goss J.R., Taffe K.M., Kochanek P.M., DeKosky S.T. The antioxidant enzymes glutathione peroxidase and catalase increase following traumatic brain injury in the rat. Exp. Neurol. 146:1997;291-294.
210. Douglas K.T. Mechanism of action of glutathione-dependent enzymes. Adv. Enzymol. Relat. Areas Mol. Biol. 59:1987;103-167.
211. 2 cells exposed to oxidative stress or glutathione depletion. Arch. Biochem. Biophys. 342:1997;126-133.
212. Pena L.R., Hill B.B., McClain C.J. Treatment with glutathione precursor decreases cytokine activity. JPEN J. Parenter. Enteral. Nutr. 23:1999;1-6.
213. Yamashita N., Hoshida S., Otsu K., Asahi M., Kuzuya T., Hori M. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J. Exp. Med. 189:1999;1699-1706.
214. Yamauchi N., Watanabe N., Kuriyama H., Neda H., Maeda M., Himeno T., Tsuji Y., Niitsu Y. Suppressive effects of intracellular glutathione on hydroxyl radical production induced by tumor necrosis factor. Int. J. Cancer. 46:1990;884-888.
215. Nussler A.K., Di Silvio M., Billiar T.R., Hoffman R.A., Geller D.A., Selby R., Madariaga J., Simmons R.L. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J. Exp. Med. 176:1992;261-264.
216. Jeannin P., Delneste Y., Lecoanet-Henchoz S. Thiols decrease human interleukin (IL)-4 production and IL-4-induced immunoglobulin synthesis. J. Exp. Med. 182:1995;1785-1792.
217. Gosset P., Wallaert B., Tonnel A.B., Fourneau C. Thiol regulation of the production of TNF-α, IL-6 and IL-8 by human alveolar macrophages. Eur. Respir. J. 14:1999;98-105.
218. Neuschwander-Tetri B.A., Bellezzo J.M., Britton R.S. Thiol regulation of endotoxin-induced release of tumor necrosis factor α from isolated rat Kupffer cells. Biochem. J. 320:1996;1005-1010.
219. L-Buthionine-(S,R)-sulfoximine, an irreversible inhibitor of γ-glutamylcysteine synthetase, augments pro-inflammatory cytokine biosynthesis evidence for the implication of an IκB-α/NF-κB insensitive pathway. Eur. Cytokine Netw. 12:2001;614-624.
220. Haddad J.J., Saadé N.E., Safieh-Garabedian B. Redox regulation of TNF-α biosynthesis augmentation by irreversible inhibition of γ-glutamylcysteine synthetase and the involvement of an IκB-α/NF-κB-independent pathway in alveolar epithelial cells. Cell. Signal. 14:2002;211-218.
221. Barrett E.G., Johnston C., Oberdörster G., Finkelstein J.N. Antioxidant treatment attenuates cytokine and chemokine levels in murine macrophages following silica exposure. Toxicol. Appl. Pharmacol. 158:1999;211-220.
222. L-cysteine on cytokine production and collagen-induced arthritis (CIA). Clin. Exp. Immunol. 115:1999;26-31.
223. p38-dependent regulation of pro-inflammatory cytokine production. Biochem. Pharmacol. 63:2002;305-320.
224. Nishinaka Y., Masutani H., Nakamura H., Yodoi J. Regulatory roles of thioredoxin in oxidative stress-induced cellular responses. Redox Rep. 6:2001;289-295.
225. Nishinaka Y., Nakamura H., Masutani H., Yodoi J. Redox control of cellular function by thioredoxin. A new therapeutic direction in host defense. Arch. Immunol. Ther. Exp. (Warsz.). 49:2001;285-292.
226. Ma X., Karra S., Lindner D.J., Hu J., Reddy S.P., Kimchi A., Yodoi J., Kalvakolanu D.V. Thioredoxin participates in a cell death pathway induced by interferon and retinoid combination. Oncogene. 20:2001;3703-3715.
227. L-cysteine and glutathione. Am. J. Respir. Cell Mol. Biol. 25:2001;178-185.
228. Baldwin A.S. The NF-κB and IκB proteins new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-681.
229. Baldwin A.S. The transcription factor NF-κB and human disease. J. Clin. Invest. 107:2001;3-6.
230. Takeuchi J., Hirota K., Itoh T., Shinkura R., Kitada K., Yodoi J., Namba T., Fukuda K. Thioredoxin inhibits tumor necrosis factor- or interleukin-1-induced NF-κB activation at a level upstream of NF-κB-inducing kinase. Antioxid. Redox Signal. 2:2000;83-92.
231. Pekkari K., Avila-Carino J., Bengtsson A., Gurunath R., Scheynius A., Holmgren A. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood. 97:2001;3184-3190.
232. Yodoi J. Evolution of thioredoxin and redox signaling research viewpoint. Antioxid. Redox Signal. 2:2000;629-630.
233. Barral A.M., Kallstrom R., Sander B., Rosen A. Thioredoxin, thioredoxin reductase and tumor necrosis factor-α expression in melanoma cells correlation to resistance against cytotoxic attack. Melanoma Res. 10:2000;331-343.
234. Nilsson J., Soderberg O., Nilsson K., Rosen A. Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood. 95:2000;1420-1426.
235. Ueno M., Masutani H., Arai R.J., Yamauchi A., Hirota K., Sakai T., Inamoto T., Yamaoka Y., Yodoi J., Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J. Biol. Chem. 274:1999;35809-35815.
236. Maurice M.M., Nakamura H., Gringhuis S., Okamoto T., Yoshida S., Kullmann F., Lechner S., van der Voort E.A., Leow A., Versendaal J., Muller-Ladner U., Yodoi J., Tak P.P., Breedveld F.C., Verweij C.L. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 42:1999;2430-2439.
237. Shoda L.K., Rice-Ficht A.C., Zhu D., McKown R.D., Brown W.C. Bovine T cell responses to recombinant thioredoxin of Fasciola hepatica. Vet. Parasitol. 82:1999;35-47.
238. Han B.G., Ma X.K., Meng L., Song X.G., Peng S.Y., Wang J.X., Ling S.G. Thioredoxin fusion/HIV-1 protease co-expression system for production of soluble human IL-6 in E. coli cytoplasm. Biochem. Mol. Biol. Int. 46:1998;839-846.
239. Yamada M., Tomida A., Yoshikawa H., Taketani Y., Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res. 2:1996;427-432.
240. Schallreuter K.U., Beazley W.D., Hibberts N.A., Swanson N.N., Pittelkow M.R. Perturbed epidermal pterin metabolism in Hermansky-Pudlak syndrome. J. Invest. Dermatol. 111:1998;511-516.
241. Saito I., Shimuta M., Terauchi K., Tsubota K., Yodoi J., Miyasaka N. Increased expression of human thioredoxin/adult T cell leukemia-derived factor in Sjogren's syndrome. Arthritis Rheum. 39:1996;773-782.
242. Minakawa R., Nakamura H., Holmgren A., Yodoi J., Lindholm B., Tyden G., Reinholt F.P. Expression of ATL-derived factor/human thioredoxin in rejected kidney grafts. Transplant. Proc. 28:1996;1463-1464.
243. Schenk H., Vogt M., Dröge W., Schulze-Osthoff K. Thioredoxin as a potent co-stimulus of cytokine expression. J. Immunol. 156:1996;765-771.
244. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270:1995;1230-1237.
245. Salceda S., Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272:1997;22642-22647.
246. Wenger R.H., Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378:1997;609-616.
247. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1 a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
248. Paleolog E.M., Young S., Stark A.C., McCloskey R.V., Feldmann M., Maini R.N. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 41:1998;1258-1265.
249. Haddad J.J., Land S.C. A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α FEBS Lett. 505:2001;269-274.
250. Haddad J.J. Recombinant human interleukin (IL)-1β-mediated regulation of hypoxia-inducible factor-1α (HIF-1α) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. Eur. Cytokine Netw. 13:2002;250-260.
251. Thornton R.D., Lane P., Borghaei R.C., Pease E.A., Caro J., Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem. J. 350:2000;307-312.
252. Hellwig-Bürgel T., Rutkowski K., Metzen E., Fandrey J., Jelkmann W. Interleukin-1β and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 94:1999;1561-1567.
253. Faquin W.C., Schneider T.J., Goldberg M.A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 79:1990;1987-1994.
254. Kvietikova I., Wenger R.H., Marti H.H., Gassmann M. The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int. 51:1997;564-566.
255. Fandrey J., Huwiler A., Frede S., Pfeilschifter J., Jelkmann W. Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression. Eur. J. Biochem. 226:1994;335-340.
256. Makarov S.S. NF-κB as a therapeutic target in chronic inflammation recent advances. Mol. Med. Today. 6:2000;441-448.
257. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:1986;705-716.
258. Schreck R., Albermann K., Baeuerle P.A. Nuclear factor-κB an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radic. Res. Commun. 17:1992;221-237.
259. Li N., Karin M. Is NF-κB the sensor of oxidative stress? FASEB J. 13:1999;1137-1143.
260. 193-195 receptor antagonism in the alveolar epithelium. Biochem. J. 355:2001;29-38.
261. Mercurio F., Manning A.M. Multiple signals converging on NF-κB. Curr. Opin. Cell Biol. 11:1999;226-232.
262. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2 cytokine-activated IκB kinases essential for NF-κB activation. Science. 278:1997;860-866.
263. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., KowaLczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-κB/nuclear factor-κB-sensitive pathway in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300:2002;567-576.
264. Rahman I., Mulier B., Gilmour P.S., Watchorn T., Donaldson K., Jeffery P.K., MacNee W. Oxidant-mediated lung epithelial cell tolerance the role of intracellular glutathione and nuclear factor-κB. Biochem. Pharmacol. 62:2001;787-794.
265. Heyninck K., Beyaert R. Cross talk between NF-κB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol. Cell Biol. Res. Commun. 4:2001;259-265.
266. Brennan P., O'Neill L.A. 2-Mercaptoethanol restores the ability of nuclear factor-κB (NF-κB) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrrolidine dithiocarbamate (PDTC) evidence for oxidation of glutathione in the mechanism of inhibition of NF-κB by PDTC. Biochem. J. 320:1996;975-981.
267. Piette J., Piret B., Bonizzi G., Schoonbroodt S., Merville M.P., Legrand-Poels S., Bours V. Multiple redox regulation in NF-κB transcription factor activation. Biol. Chem. 378:1997;1237-1245.
268. van den Berg R., Haenen G.R., van den Berg H., Bast A. Transcription factor NF-κB as a potential biomarker for oxidative stress. Br. J. Nutr. 86:2001;S121-S127.
269. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:2001;372-377.
270. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am. J. Pathol. 159:2001;387-397.
271. Wardle N. New vistas in anti-inflammatory therapy. Nephron. 88:2001;289-295.
272. Hawiger J. Innate immunity and inflammation a transcriptional paradigm. Immunol. Res. 23:2001;99-109.
273. Joyce D., Albanese C., Steer J., Fu M., Bouzahzah B., Pestell R.G. NF-κB and cell-cycle regulation the cyclin connection. Cytokine Growth Factor Rev. 12:2001;73-90.
274. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 107:2001;135-142.
275. Hazzalin C.A., Mahadevan L.C. MAPK-regulated transcription a continuously variable gene switch? Nat. Rev. Mol. Cell Biol. 3:2002;30-40.
276. Arbabi S., Maier R.V. Mitogen-activated protein kinases. Crit. Care Med. 30:2002;S74-S79.
277. Hagemann C., Blank J.L. The ups and downs of MEK kinase interactions. Cell. Signal. 13:2001;863-875.
278. Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway paradigms of multiplicity. Cell. Signal. 13:2001;777-785.
279. Gudermann T. Multiple pathways of ERK activation by G protein-coupled receptors. Novartis Found. Symp. 239:2001;68-79.
280. Dong C., Davis R.J., Flavell R.A. Signaling by the JNK group of MAP kinases c-jun N-terminal kinase. J. Clin. Immunol. 21:2001;253-257.
281. Ballif B.A., Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12:2001;397-408.
282. Marinissen M.J., Gutkind J.S. G-protein-coupled receptors and signaling networks emerging paradigms. Trends Pharmacol. Sci. 22:2001;368-376.
283. Pearson G., Robinson F., Beers, Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways regulation and physiological functions. Endocr. Rev. 22:2001;153-183.
284. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:2001;807-869.
285. Chang L., Karin M. Mammalian MAP kinase signaling cascades. Nature. 410:2001;37-40.
286. Kyriakis J.M. MAP kinases and the regulation of nuclear receptors. Sci. STKE. 2000:2000;PE1.
287. Garrington T.P., Johnson G.L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11:1999;211-218.
288. Su B., Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr. Biol. 8:1996;402-411.
289. Haan J., Lee J.D., Bibbs L., Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:1994;808-811.
290. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev. 4:1994;82-89.
291. Cano E., Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20:1995;117-122.
292. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:1997;180-186.
293. Haddad J.J. VX-745 Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs. 2:2001;1070-1076.
294. De Keulenaer G.W., Ushio-Fukai M., Yin Qiqin Chung A.B., Lyons P.R., Ishizaka N., Rengarajan K., Taylor W.R., Alexander R.W., Griendling K.K. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-α-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20:2000;385-391.
295. Kang K.W., Ryu J.H., Kim S.G. The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE cells. Mol. Pharmacol. 58:2000;1017-1025.
296. Hashimoto S., Gon Y., Matsumoto K., Takeshita I., Horie T. N-Acetylcysteine attenuates TNF-α-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br. J. Pharmacol. 132:2001;270-276.
297. Adams J.L., Badger A.M., Kumar S., Lee J.C. p38 MAP kinase molecular target for the inhibition of pro-inflammatory cytokines. Prog. Med. Chem. 38:2001;1-60.
298. Zvalova D., Formstecher E., Fauquet M., Canton B., Chneiweiss H. Keeping TNF-induced apoptosis under control in astrocytes PEA-15 as a 'double key' on caspase-dependent and MAP-kinase-dependent pathways. Prog. Brain Res. 132:2001;455-467.
299. Petak I., Houghton J.A. Shared pathways death receptors and cytotoxic drugs in cancer therapy. Pathol. Oncol. Res. 7:2001;95-106.
300. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., Legos J.J., Erhardt J.A., Ohlstein E.H., Hunter A.J., Harrison D.C., Philpott K., Smith B.R., Adams J.L., Parsons A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 21:2001;129-145.
301. Berra E., Pages G., Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19:2000;139-145.
302. Hall J.P., Merithew E., Davis R.J. c-Jun N-terminal kinase (JNK) repression during the inflammatory response? Just say NO. Proc. Natl. Acad. Sci. USA. 97:2000;14022-14024.
303. Park H.S., Park E., Kim M.S., Ahn K., Kim I.Y., Choi E.J. Selenite inhibits the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J. Biol. Chem. 275:2000;2527-2531.
304. Vanden-Berghe W., Vermeulen L., De Wilde G., De Bosscher K., Boone E., Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem. Pharmacol. 60:2000;1185-1195.
305. Carter A.B., Knudtson K.L., Monick M.M., Hunninghake G.W. The p38 mitogen-activated protein kinase is required for NF-κB-dependent gene expression the role of TATA-binding protein (TBP). J. Biol. Chem. 274:1999;30858-30863.